IQIRVO® (elafibranor) | Official Patient Site IQIRVO is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well to UDCA, or used alone in patients unable to tolerate UDCA
Treatment For PBC | IQIRVO® (elafibranor) | Official HCP Site IQIRVO ® is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA
label - Food and Drug Administration IQIRVO is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well to UDCA, or used alone in
Ipsen’s Iqirvo® receives U. S. FDA accelerated approval as a . . . - Global Iqirvo has been submitted to the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA), seeking authorization for PBC, with final EMA and MHRA regulatory decisions anticipated in the second half of 2024
Iqirvo: A New Treatment Option for Primary Biliary Cholangitis Iqirvo (elafibranor) is a medicine that can help treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body It does this by signaling the body to stop making bile acid
Iqirvo (Elafibranor) for PBC - myPBCteam Iqirvo belongs to the peroxisome proliferator-activated receptors (PPAR) agonist category It works by activating PPARs, which play a role in regulating inflammation and metabolism in the liver
PBC treatment | IQIRVO® (elafibranor) Support Resources IQIRVO is indicated for adults with primary biliary cholangitis (PBC) IQIRVO is an add-on treatment, meaning it is taken alongside ursodiol However, in people who are unable to take ursodiol, IQIRVO can be taken alone Talk to your doctor to see if IQIRVO is right for you